Superworth

Arrowhead Pharmaceuticals EV/EBIT ARWR

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2019.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
32.8×
May 2026
7-year median
79.0×
7-year range
23.6× to 440×
Peer median
54.6×

Arrowhead Pharmaceuticals has no meaningful EV/EBIT today: it made an operating loss of $226.4M over the last twelve months.

It was last meaningful in May 2026, at 32.8×.

On the days it had one over the last 7 years, its median was 79.0×, from 23.6× in Mar 2026 to 440× in Jul 2019.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far32.8×23.6×90.5×
202591.6×67.5×91.6×
2024n/m a value too high to mean anything
2023n/m a value too high to mean anything
2022n/m a value too high to mean anything
2021n/m a value too high to mean anything
202062.2×47.8×92.0×
201997.3×57.7×440×

Against its peers

Companies in Drug Manufacturers - General nearest Arrowhead Pharmaceuticals' size, closest first, today.

CompanyEV/EBIT
ARWRArrowhead Pharmaceuticalsn/m
TGTXTG Therapeutics62.2×
PTGXProtagonist Therapeutics140×
ALKSAlkermes plc.69.6×
CORTCorcept Therapeuticsn/m
AMRXAmneal Pharmaceuticals18.3×
BMRNBiomarin Pharmaceutical25.8×
LGNDLigand Pharmaceuticals57.7×
KNSAKiniksa Pharmaceuticals International54.6×
JAZZJazz Pharmaceuticals15.9×
INDVIndivior Pharmaceuticals7.8×
Peer median54.6×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Arrowhead Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.